Albemarle Corp SEC Filings

Advent Technologies Holdings, Inc. (NASDAQ: ADN) filed an 8-K announcing two material events dated July 1, 2025.

1 – Settlement Agreement: The company resolved its previously disclosed dispute with F.E.R. fischer Edelstahlrohre GmbH stemming from a June 25, 2021 share-purchase agreement. Advent will pay Fischer €5,366,625.55 in instalments beginning September 1, 2025. If the total amount is remitted by June 30, 2026, the liability is reduced to €4,366,625.55. In exchange, both parties executed a mutual release of all claims, fully terminating the litigation risk.

2 – Nasdaq Compliance: Advent received a letter from Nasdaq’s Listing Qualifications Department confirming it has regained compliance with Listing Rule 5250(c)(1) after filing its Quarterly Report for the period ended March 31, 2025. The company’s common stock (ADN) and warrants (ADNWW) therefore remain listed on The Nasdaq Stock Market LLC.

Investor takeaway: The 8-K removes two significant overhangs—outstanding litigation and potential delisting—but introduces a cash commitment of up to €5.37 million over the next 12 months, partially mitigated by a €1 million discount for early payment.

Albemarle Corporation (ALB) – Form 4 Insider Transaction

Director James J. O’Brien reported two share acquisitions dated 1 July 2025:

• 2,725 common shares granted as the annual installment of non-employee director compensation under the company’s 2023 Stock Compensation and Deferral Election Plan. These shares are scheduled to vest on 1 July 2026.
• 37 common shares issued in lieu of cash dividends that accrued on a prior award granted 1 July 2024 and fully vested on 1 July 2025.

Both transactions were reported with a $0.00 acquisition price, indicating they are equity compensation rather than open-market purchases. Following the two grants, O’Brien’s direct beneficial ownership increased to 8,085 common shares.

No derivative securities were reported and no dispositions occurred. An Exhibit 24 Power of Attorney was filed to authorize the attorney-in-fact signature.

The filing is routine, reflecting scheduled director equity awards rather than discretionary insider buying or selling.

Albemarle Corporation (ALB) – Form 4 insider filing dated 07/03/2025

Non-employee director Ralf Hans Cramer reported routine equity transactions related to the company’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors:

• Grant of 2,725 common shares on 07/01/2025 as the director’s annual equity retainer; the shares vest on 07/01/2026.
• Tax withholding: 602 previously granted shares were forfeited at an imputed price of $62.90 to satisfy tax obligations upon vesting of the 07/01/2024 award.
• Dividend equivalents: 37 additional shares were issued in lieu of cash dividends on the 2024 award; 13 of those shares were simultaneously withheld at the same $62.90 price to cover related taxes.

After the transactions, the director’s direct beneficial ownership totals 5,379 ALB shares. No derivative securities were reported.

The filing is administrative and compensation-related; it does not disclose any open-market purchases or sales that would typically signal a directional view on the stock. The dollar value of shares involved is modest relative to Albemarle’s market capitalization and daily volume, and therefore the transaction is unlikely to be material for investors.

Albemarle Corporation (ALB) – Form 4 insider filing dated 07/03/2025

Non-employee director Ralf Hans Cramer reported routine equity transactions related to the company’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors:

• Grant of 2,725 common shares on 07/01/2025 as the director’s annual equity retainer; the shares vest on 07/01/2026.
• Tax withholding: 602 previously granted shares were forfeited at an imputed price of $62.90 to satisfy tax obligations upon vesting of the 07/01/2024 award.
• Dividend equivalents: 37 additional shares were issued in lieu of cash dividends on the 2024 award; 13 of those shares were simultaneously withheld at the same $62.90 price to cover related taxes.

After the transactions, the director’s direct beneficial ownership totals 5,379 ALB shares. No derivative securities were reported.

The filing is administrative and compensation-related; it does not disclose any open-market purchases or sales that would typically signal a directional view on the stock. The dollar value of shares involved is modest relative to Albemarle’s market capitalization and daily volume, and therefore the transaction is unlikely to be material for investors.

Albemarle Corporation (ALB) – Form 4 insider filing dated 07/03/2025

Non-employee director Alejandro Daniel Wolff reported two routine equity transactions carried out under the company’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors:

• Common stock dividend equivalents: 37 shares were credited on 07/01/2025 as dividend equivalents on a prior equity award that vested the same day. These shares were acquired at $0 cost, bringing the director’s directly held common stock to 12,539 shares.
• Phantom stock grant: 2,725 phantom stock units (1-for-1 convertible into common shares) were awarded on 07/01/2025. The units vest on 07/01/2026 and have no stated expiration date. Including this grant and associated dividend equivalents, the director now holds 6,278 phantom stock units.

No sales or dispositions were reported. The transactions were made at $0 price and do not involve open-market purchases or sales. As Wolff remains on the board, these grants represent standard annual director compensation and dividend accruals rather than signal-bearing insider buying or selling.

Overall, the filing reflects normal course equity accrual that slightly increases insider alignment but is immaterial to Albemarle’s share count or valuation. There is no indication of strategic intent or upcoming corporate events.

Albemarle Corporation (ALB) – Form 4 insider transaction filing

Director Dean Seavers reported two equity awards dated 1 July 2025:

• 2,725 common shares granted under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors; the award vests on 1 July 2026.
• 37 additional shares issued as accrued dividends on a July 2024 award that vested in full on 1 July 2025.

No shares were sold and no derivative securities were transacted. Following the awards, Seavers’ total direct beneficial ownership rose to 12,021 common shares. The transactions were effected at a stated price of $0, reflecting their nature as board compensation rather than open-market purchases.

The filing is routine for annual director compensation but does increase insider equity alignment and signals continued board participation in Albemarle’s long-term incentive structure.

Medicus Pharma Ltd. (Nasdaq: MDCX) has filed Prospectus Supplement No. 6 to its May 29, 2025 prospectus in connection with the potential resale of up to 3,710,000 common shares. The supplement attaches Amendment No. 1 to the Company’s June 30, 2025 Current Report, which formally files and incorporates by reference a Share Exchange Agreement dated June 29, 2025 among Medicus, Antev Limited and Antev security-holders.

The Agreement—filed as Exhibit 2.1—sets out the framework for a contemplated transaction involving Antev and the oncology/uro-oncology candidate Teverelix. While financial terms remain redacted, management states that the deal is expected to advance and commercialize Teverelix and open new market opportunities. The filing does not amend any other disclosures contained in the original 8-K.

The Company reiterates its emerging-growth-company status and reminds investors to review the “Risk Factors” section beginning on page 9 of the original prospectus. Shares continue to trade on the Nasdaq Capital Market; the most recent closing price (July 2, 2025) was $3.22.

No updated financial statements or pro-forma data are included in this supplement. Investors should therefore focus on potential dilution from the 3.71 million shares and on execution risks surrounding the Antev transaction, which is still subject to customary conditions.

Hamilton Beach Brands Holding Co. (HBB) filed a Form 4 for director Alfred M. Rankin, Jr. covering a single transaction on 07/01/2025. Acting as trustee for a family trust, Rankin acquired 2,156 Class A common shares classified as “Required Shares” under the company’s Non-Employee Directors’ Equity Compensation Plan; footnote 2 confirms the shares were received with no cash consideration (price N/A).

After the award, the trust’s position rose to 361,551 shares. The filing also lists other indirect holdings: 14,160 shares in an IRA for Rankin and trusts holding 11,076 and 69,872 shares for family members, for which he disclaims beneficial ownership. No derivative securities, sales, or additional acquisitions were reported.

The transaction reflects routine board compensation rather than an open-market buy and represents a modest percentage of Rankin’s existing indirect holdings, implying limited immediate market impact but continued insider alignment with shareholder interests.